Email this article Novel Pyran and Polyhydroquinoline Derivatives: Inhibiting Human Osteosarcoma Activity
- Authors: Fan X.1, Shen P.1, Zhou X.1
-
Affiliations:
- Department of Orthopaedics
- Issue: Vol 88, No 6 (2018)
- Pages: 1247-1251
- Section: Article
- URL: https://journals.rcsi.science/1070-3632/article/view/222271
- DOI: https://doi.org/10.1134/S1070363218060336
- ID: 222271
Cite item
Open Access
Access granted
Subscription Access
Abstract
A series of pyran 1–6 and polyhydroquinoline derivatives 7–9 are synthesized targeting anticancer agents for clinical trials. Their structures are characterized by IR, 1H NMR, and HRMS spectra, and single crystal X-ray crystallography. Their anticancer activity against four human osteosarcoma cells (Saos-2, MG-63, 143B, and U2-OS) is evaluated in vitro using the MTT assay. The compounds 7–9 demonstrate high anticancer activity against the four cancer cells.
Keywords
About the authors
X.-X. Fan
Department of Orthopaedics
Email: xinhua_zhou666@yeah.net
China, Huzhou, Zhejiang, 313003
P. Shen
Department of Orthopaedics
Email: xinhua_zhou666@yeah.net
China, Huzhou, Zhejiang, 313003
X.-H. Zhou
Department of Orthopaedics
Author for correspondence.
Email: xinhua_zhou666@yeah.net
China, Huzhou, Zhejiang, 313003
